Paradigm Biopharmaceuticals Ltd has released a press release.
Paradigm reports consistent oa pain reduction
Filed with ASX ·
6ix hasn’t read this filing yet.
Paradigm Biopharmaceuticals Ltd. on 6ix
Earlier from Paradigm Biopharmaceuticals
- Paradigms AGM Presentation
- Paradigm in-licenses treatment for rare joint disease
- Paradigm receives $2.32m R&D tax incentive refund
- PAR reports pain reduction in 145 people with osteoarthritis
- Paradigm Agreement With USA Past Players Network
Later from Paradigm Biopharmaceuticals
- PAR reports successful phase 2 clinical trial
- Presentation of phase 2 clinical trial results
- Paradigms supplementary phase 2B data
- Paradigms orphan phase 2/3 clinical program progresses
- S&P DJI Announces March 2019 Quarterly Rebalance
Follow Paradigm Biopharmaceuticals into a list and get an email when it puts out news.
Follow Paradigm Biopharmaceuticals